Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00225862 · ClinicalTrials.gov registry record · Phase 3
A Clinical Research Study Evaluating Ropinirole Treatment For Restless Legs Syndrome (RLS)
A Phase 3 study, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 3
- Development phase
- 140
- Enrollment target
NCT00225862 is a Phase 3 study that has completed, run by GlaxoSmithKline. The registered enrollment target is 140 participants.
The verdict
NCT00225862, a Phase 3 study, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 140 participants
- Enrollment target
Study Summary
A 12-week clinical research study to evaluate the tolerability, efficacy and safety of ropinirole compared to placebo(an inactive sugar pill) in the treatment of patients with RLS in the United States.
Interventions
- DRUG ropinirole
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 140 participants |
| Start Date | 2005-01 |
| Est. Completion | 2005-12 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00225862
The ClinicalTrials.gov registry entry for NCT00225862 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 140 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which ropinirole is the first listed.
NCT00225862 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00225862 about?
NCT00225862 is a clinical study titled "A Clinical Research Study Evaluating Ropinirole Treatment For Restless Legs Syndrome (RLS)". A 12-week clinical research study to evaluate the tolerability, efficacy and safety of ropinirole compared to placebo(an inactive sugar pill) in the treatment of patients with RLS in the United States.
What is the current status of trial NCT00225862?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 140 participants. The study started on 2005-01. Estimated completion is 2005-12.
What interventions are being tested in trial NCT00225862?
The interventions under investigation include: ropinirole (DRUG).
Who is sponsoring clinical trial NCT00225862?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.